Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response

Journal of Neuroimmunology

Volumn 225, Issue 1-2, 2010, Pages 153-163

  Kovalchin, J ^a   Krieger, J ^a   Genova, M ^a   Collins, K ^a   Augustyniak, M ^a   Masci, A ^a   Hittinger, T ^a   Kuca, B ^a   Edan, G ^b   Braudeau, C ^c   Rimbert, M ^c   Patel, U ^a   Mascioli, E ^a   Zanelli, E ^a  

^a Peptimmune Inc   (United States)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

Author keywords

Immunomodulatory therapy; Interleukin 13; Multiple sclerosis; Pharmacokinetics; Serum biomarkers; Th2 immunity

Indexed keywords

CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 3; MACROPHAGE DERIVED CHEMOKINE; PI 2301; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; FEMALE; HUMAN; HUMAN CELL; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OPEN STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TH2 CELL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PEPTIDES; SEVERITY OF ILLNESS INDEX; TH2 CELLS; TREATMENT OUTCOME;

EID: 77955663455     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.04.008     Document Type: Article

References (38)

1. Andrew D.P., Chang M., McNinch J., Wathen S.T., Rihanek M., Tseng J., Spellberg J.P., Elias C.G. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J. Immunol. 1998, 161:5027-5038.
2. Asquith K.L., Ramshaw H.S., Hansbro P.M., Beagley K.W., Lopez A.F., Foster P.S. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of the Th2 immunity and allergic airway inflammation. J. Immunol. 2008, 180:1199-1206.
3. Bargagli E., Mazzi A., Mezzasalma F., Perrone A., Olivieri C., Prasse A., Bianchi N., Pieroni M.G., Rottoli P. The analysis of tryptase in serum of sarcoidosis patients. Inflammation 2009, 32:310-314.
4. Boggild M. Immunosuppression followed by immunomodulation. J. Neurol. Sci. 2009, 277:S50-S54.
5. Columba-Cabezas S., Serafini B., Ambrosini E., Sanchez M., Penna G., Adorini L., Aloisi F. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. 2002, 130:10-21.
6. Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol. Sci. 2009, 30:S155-S158.
7. Comi G., Filippi M., Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 2001, 49:290-297.
8. De Stefano N., Filippi M., Confavreux C., Vermersch P., Simu M., Sindic C., Hupperts R., Bajenaru O., Edan G., Grimaldi L., Marginean I., Medaer R., Orefice G., Pascu I., Pelletier J., Sanders E., Scarpini E., Mancardi G.L. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 2009, 15:238-243.
9. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein 1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009, 29:313-326.
10. Dhib-Jalbut S. Glatiramer acetate (Copaxone®) therapy for multiple sclerosis. Pharmacol. Ther. 2003, 98:245-255.
11. Dressel A., Mirowska-Guzel D., Gerlach C., Wber F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta Neurol. Scand. 2007, 116:164-168.
12. Ebner S., Hofer S., Nguyen V.A., Furhapter C., Herold M., Fritsch P., Heufler C., Romani N. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. J. Immunol. 2002, 168:6199-6207.
13. Eri R., Kodumudi K.N., Summerlin D.J., Srinivasan M. Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14:458-470.
14. Finkelman F.D. Anaphylaxis: lessons from mouse models. J. Allergy Clin. Immunol. 2007, 120:506-515.
15. Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O.J., Brenner T., Arnon R., Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4872-4876.
16. Fridkis-Hareli M., Santambrogio L., Stern J.N.H., Fugger L., Brosnan C., Strominger J.L. Novel synthetic amino acid copolymers that inhibit autoantigen-specfic T cell responses and suppress experimental autoimmune encephalomyelitis. J. Clin. Investig. 2002, 109:1635-1643.
17. Gauthier L., Smith K.J., Pyrdol J., Kalandadze A., Strominger J.L., Wiley D.C., Wucherpfennig K.W. Expression and crystallization of the complex HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:11,828-11,833.
18. Gu L., Tseng S., Horner R.M., Tam C., Loda M., Rollins B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404:407-411.
19. Herman S., Zurgil N., Langevitz P., Ehrenfeld M., Deutsch M. Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin. Exp. Rheumatol. 2008, 26:317-323.
20. Illés Z., Stern J.N.H., Reddy J., Waldner H., Mycko M.P., Brosnan C.F., Ellmerich S., Altmann D.M., Santambrogio L., Strominger J.L., Kuchroo V.K. Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11,749-11,754.
21. Inglese M., van Waesberghe J.H., Rovaris M., Beckmann K., Barkhof F., Hahn D., Kappos L., Miller D.H., Polman C., Pozzilli C., Thompson A.J., Yousry T.A., Wagner K., Comi G., Filippi M. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 2003, 60:853-860.
22. Jarius, S., Hohlfeld, R., Voltz, R., 2003. Diagnosis and treatment of multiple sclerosis. Update, 2003. M.M.W. Fortschr. Med. 145, 88-91, 93, 95.
23. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
24. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
25. Martinelli V., Radaelli M., Straffi L., Rodegher M., Comi G. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol. Sci. 2009, 30:S167-S170.
26. Maurer M., von Stebut E. Macrophage inflammatory protein-1. Int. J. Biochem. Cell Biol. 2004, 36:1882-1886.
27. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 1998, 92:113-121.
28. Nakayama T., Yamashita M. Initiation and maintenance of Th2 cell identity. Curr. Opin. Immunol. 2008, 20:265-271.
29. + Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J. Immunol. 2009, 182:5317-5321.
30. Papeix C., Lubetzki C. Monoclonal antibodies in multiple sclerosis. Med. Sci. (Paris) 2009, 25:1113-1115.
31. Prat A., Biernacki K., Antel J.P. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J. Autoimmun. 2005, 24:119-124.
32. Saito H., Kato A., Matsumoto K. Role of mast cells in allergy. Nippon Rinsho 2009, 67:2083-2087.
33. Sanna A., Fois M.L., Arru G., Huang Y.M., Link H., Pugliatti M., Rosati G., Sotgiu S. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 ad IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin. Exp. Immunol. 2006, 143:357-362.
34. Stern J.N.H., Illés Z., Reddy J., Keskin D.B., Sheu E., Fridkis-Hareli M., Nishimura H., Brosnan C.F., Santambrogio L., Kuchroo V.K., Strominger J.L. Amelioration of proteolipid protein 139-151-induces encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11,743-11,748.
35. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1:242-248.
36. Varkony H., Weinstein V., Klinger E., Sterling J., Cooperman H., Komlosh T., Ladkani D., Schwartz R. The glatiramoid class of immunomodulator drugs. Expert Opin. Pharmacother. 2009, 10:657-668.
37. Wolinsky J.S., Comi G., Filippi M., Ladkani D., Kadosh S., Shifroni G. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 2002, 59:1284-1286.
38. Ziemssen T., Neuhaus O., Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 2001, 24:979-990.